Stockscreener 앱 받기
155.51
1.14%
1.76
시간 외 거래:
155.51
전일 마감가:
$153.75
열려 있는:
$154.47
하루 거래량:
893.06K
Relative Volume:
0.95
시가총액:
$15.51B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
52.72
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+2.20%
1개월 성능:
+1.14%
6개월 성능:
+24.80%
1년 성능:
+23.01%
1일 변동 폭
$153.38
$156.76
1주일 범위
$149.58
$156.76
52주 변동 폭
$84.23
$157.67
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
155.51 | 15.38B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
118.65 | 53.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 45.11B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.44B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.46 | 32.59B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
489.31 | 20.84B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences (NBIX) valuation update after NBI-1070770 Phase 2 trial failure reshapes pipeline expectations - simplywall.st
Earnings Recap: How Neurocrine Biosciences Inc stock performs in weak economyWeekly Trade Report & High Accuracy Trade Alerts - BỘ NỘI VỤ
TD Cowen Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc. - MarketBeat
TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Biotech Leader Neurocrine Biosciences Stock Fights To Regain Buy Point At Key Resistance Level - Investor's Business Daily
Saturn V Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Will Neurocrine Biosciences Inc. stock split again soonWeekly Loss Report & Free Fast Gain Swing Trade Alerts - Newser
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen By Investing.com - Investing.com South Africa
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen - Investing.com India
Why Neurocrine Biosciences Inc. (NB3) stock stays on buy listsPortfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
Dodge & Cox Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
U.S. Tardive Dyskinesia Treatment Market to Reach USD 6417.43 - openPR.com
Will Neurocrine Biosciences Inc. (NB3) stock beat growth indexesOil Prices & Accurate Technical Buy Alerts - Newser
Is Neurocrine Biosciences Stock Built to Withstand a Pullback? - Trefis
Lyons (Neurocrine Biosciences director) sells $2.29m in NBIX stock - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing - marketscreener.com
Dir Lyons Sells 15,000 ($2.3M) Of Neurocrine Biosciences Inc [NBIX] - TradingView
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockWeekly Trend Summary & Real-Time Buy Zone Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyDollar Strength & Growth Oriented Trade Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock benefit from sector leadershipPortfolio Profit Report & Expert Verified Stock Movement Alerts - Newser
Will Neurocrine Biosciences Inc. (NB3) stock gain from green policies2025 Institutional Moves & Weekly High Potential Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock remains top ratedMarket Trend Summary & Daily Technical Forecast Reports - Newser
Fisher Asset Management LLC Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Earnings Notes - Trefis
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Dir Lyons Files To Sell 15,000 Of Neurocrine Biosciences Inc [NBIX] - TradingView
Sio Capital Management LLC Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Mackenzie Financial Corp Has $9.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Norges Bank Takes Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hsbc Holdings PLC - MarketBeat
Korea Investment CORP Cuts Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Russell Investments Group Ltd. Has $10.58 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Can Neurocrine Biosciences Inc. stock attract ESG capital inflowsJuly 2025 Drop Watch & Consistent Growth Stock Picks - Newser
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock - MSN
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Neurocrine Biosciences Executive Sells Shares - TradingView
Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing - marketscreener.com
Officer Benevich Sells 5,970 ($905.9K) Of Neurocrine Biosciences Inc [NBIX] - TradingView
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Virtus Advisers LLC - MarketBeat
Loomis Sayles & Co. L P Acquires New Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZA’s Clinical Profile - simplywall.st
Edgestream Partners L.P. Takes $9.25 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Distillate Capital Partners LLC Sells 8,175 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusQuarterly Profit Report & Growth Focused Entry Reports - Newser
Neurocrine Biosciences chief corporate affairs officer sells $82,820 in stock - MSN
Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating - marketscreener.com
Skandinaviska Enskilda Banken AB publ Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Quadrature Capital Ltd Purchases 11,162 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Inceptionr LLC Takes Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
0.41%
자본화:
|
볼륨(24시간):